NEWS

Axcelead DDP participates in “MONSTAR-SCREEN-2” of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan “SCRUM-Japan”, as a joint research institute

2021.10.25

We are pleased to announce that Axcelead Drug Discovery Partners Inc., (Headquarters: Fujisawa, Kanagawa, JAPAN, CEO: Yoshinori Ikeura, hereinafter “Axcelead DDP”) will participate as a joint research institution to support “MONSTAR-SCREEN-2” of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan “SCRUM-Japan” led by the National Cancer Center Hospital East (Location: […]

Axcelead has entered into a comprehensive agreement including transfer of key drug discovery platforms with a major Japanese pharmaceutical company

2021.10.18

Axcelead Drug Discovery Partners Co., Ltd. (Headquarters: Fujisawa, Kanagawa, President, CEO: Yoshinori Ikeura; Axcelead) announces that the company has strengthened the platforms including high-throughput screening (HTS), high-throughput ADME (metabolism & pharmacokinetics) and TOX (safety) studies (HT-ADMET), based on a comprehensive business transfer agreement with a major Japanese pharmaceutical company (hereinafter, referred to as “the pharmaceutical company”). […]

Evommune and Axcelead Drug Discovery Partners Launch A Collaboration On A PKCtheta Program To Kick-off Evommune’s Inflammation Pipeline

2020.12.10

Inhibition of PKCtheta as a therapeutic target has the potential to treat multiple inflammatory diseases Los Altos, California, USA and Fujisawa, Kanagawa, Japan – Dec. 10, 2020 – Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, and Axcelead Drug Discovery Partners, Inc. (Axcelead), a Japanese solution provider in drug discovery research, […]

  • A-Hit
  • Partnership・Collaboration

Axcelead and Kyowa Kirin Started an Innovative
Collaboration in Small-Molecule Drug Development

2020.10.02

Tokyo, Japan, October 2, 2020 —Axcelead Drug Discovery Partners Inc.(Axcelead, President: Yoshinori Ikeura)and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto) announce that the companies have started collaboration on the development of innovative small-molecule drugs based on a novel drug discovery technology platform. By integrating Axcelead ‘s broad range of small-molecule […]

  • Small molecule
  • Partnership・Collaboration
  • New Core Technologies

Otsuka Pharmaceutical and Axcelead Drug Discovery Partners announce
joint research in ​​CNS indications

2020.06.17

June 29,2020- Otsuka Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President: Makoto Inoue; Otsuka Pharmaceutical) and Axcelead Drug Discovery Partners Co., Ltd. (Headquarters: Fujisawa, Kanagawa, President: Yoshinori Ikeura; Axcelead) announce a collaborative drug discovery research using the Axcelead Hit-identified Target (A-HiT) project* in the area of central nervous system diseases. Axcelead is the first comprehensive integrated […]

  • A-Hit
  • Partnership・Collaboration

PassPort Technologies and Axcelead Drug Discovery Partners

2019.10.01

Enter a comprehensive collaborative partnership in the field of drug discovery service using PassPort System, a new active transdermal drug delivery technology Contribute to maximizing R&D pipeline value though providing a new modality PassPort Technologies, Inc. (President and CEO: Tomoyuki Fujisawa, California, USA) (PPTI) and Axcelead Drug Discovery Partners Co., Ltd. (President: Yoshinori Ikeura, Fujisawa, […]

  • Biologics
  • Mid-size molecule
  • Partnership・Collaboration

Fujifilm and Axcelead Drug Discovery Partners begin collaborating
to advance drug discovery solutions using iPSCs

2019.07.10

To enhance the Process of Research and Development of Drug Candidates Tokyo/Kanagawa, July 10, 2019 ―FUJIFILM Corporation (President: Kenji Sukeno; Fujifilm) and Axcelead Drug Discovery Partners Inc. (President: Yoshinori Ikeura; Axcelead) announced a collaboration to provide customers with a human induced pluripotent stem cell (iPSC)-based integrated platform for drug discovery solutions. By combining Fujifilm’s iPSC-derived […]

  • Partnership・Collaboration
  • Cardiotoxicity Assessment

Transfer of All Axcelead Shares to Whiz Partners DDG Fund Completed

2019.04.01

April 1, 2019 – Whiz Partners Inc. (hereinafter, “Whiz”), headquartered in Minato Ward, Tokyo, announced that it has completed an investment-in-kind to the “Drug Discovery Gateway Investment Limited Partnership” (hereinafter, “DDG Fund”) of issued Axcelead Drug Discovery Partners Inc. (hereinafter, “Axcelead”) shares held by Takeda Pharmaceutical Co., Ltd. (hereinafter, “Takeda”), headquartered in Chuo Ward, Osaka. […]

  • About Us

Axcelead Drug Discovery Partners and ERS Genomics Enter into CRISPR/Cas9 License Agreement

2018.10.17

Fujisawa, Japan and Dublin, Ireland, October 4, 2018 – Axcelead Drug Discovery Partners, Inc.(hereinafter referred to as “Axcelead”) and ERS Genomics Limited (hereinafter referred to as “ERS Genomics”) announced today a non-exclusive license agreement to provide Axcelead with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property to enhance their drug discovery service offering. […]

  • License
  • Genetically modified mouse/rat

Announcement on starting preparation to become a company independent from Takeda

2018.08.03

We are pleased to announce that Axcelead Drug Discovery Partners Inc. (“Axcelead”) preparation to become a company independent from Takeda Pharmaceutical Company Limited (“Takeda”) as a core company of “Drug Discovery Gateway Investment Limited Partnership” (“DDG Fund”). Under the terms of the agreement between Takeda and Japan-based Alternative Asset Management Firm, Whiz Partners, Inc. (“Whiz”), […]

  • About Us

Announcement of Start of Business Partnership between Axcelead and LAP&P for Modeling and Simulation of Drug Discovery

2018.05.30

We are pleased to announce that Axcelead Drug Discovery Partners, Inc. (Yoshinori Ikeura, President; Headquarters: Fujisawa-shi, Kanagawa, Japan; hereinafter referred to as “Axcelead”) and Leiden Experts on Advanced Pharmacokinetics & Pharmacodynamics Consultants BV (Henk-Jan Drenth, Managing Director; Headquarters: Leiden, the Netherlands; hereinafter referred to as “LAP&P”) decided to develop a business partnership for services provided […]

  • Clinical PK/PD Prediction
  • Partnership・Collaboration